$AGEN News

B. Riley Securities Maintains Buy on Agenus, Raises Price Target to $14

Agenus Surges 83% On $340 Million Financing: The Road To A 2030 Breakthrough

Agenus Inc. (AGEN) Discusses Financing and Robin Trial Strategy for Neoadjuvant Immunotherapy in MSS Colon Cancer - Slideshow

Agenus Inc. (AGEN) Discusses Financing and Robin Trial Strategy for Neoadjuvant Immunotherapy in MSS Colon Cancer Transcript

HC Wainwright & Co. Maintains Buy on Agenus, Raises Price Target to $30

Agenus Stock Soars Over 100% as BATTMAN Takes a Back Seat to ROBBIN

Agenus To Raise $85M To Fund Colon Cancer Drug Trial, Financing Could Reach $340M If Warrants Are Exercised

Agenus Presents 3-Yr Landmark Phase 1b Data From Fully Enrolled C-800-01 Cohort Evaluating Botensilimab Plus Balstilimab In Patients With Refractory MSS mCRC Without Active Liver Metastases At ESMO GI 2026

Agenus To Present 3-Yr Survival Data From Phase 1b C-800-01 Study Of Botensilimab Plus Balstilimab In Patients With Microsatellite Stable mCRC Without Active Liver Metastases At ESMO GI 2026

Agenus: Weighing The Clinical Progress Against The Company's Cash

Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

Agenus Reports Durable Survival And Deep Responses With Botensilimab Plus Balstilimab In Heavily Pretreated Checkpoint-Resistant Melanoma, Including 16.6-Month Median OS and 42% Two-Year Survival

Agenus' Noetik TARIO-2 AI Model Identifies Tumor Microenvironment Signature Predicting 64% Response Rate And Markedly Improved Survival In MSS Metastatic Colorectal Cancer Treated With Botensilimab Plus Balstilimab

Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer

Agenus Announces Publication Of Phase 1b Data Evaluating Botensilimab In Combination With Balstilimab In Patients With Treatment-Refractory HCC

Agenus (AGEN) Q1 Earnings and Revenues Miss Estimates

Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development

Agenus To Present Initial Phase 2 Data For Botensilimab Research Across Colorectal Cancer, Melanoma, And Translational Research At American Society Of Clinical Oncology Annual Meeting May 29 - June 2

Agenus Announces Phase II Data Showing Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab And agenT-797 in PD-1 Refractory Gastroesophageal Cancer; The Study Did Not Meet Its Primary Endpoint Of ORR